

## SUPPLEMENTARY TABLES

**Supplementary Table 1. Antibodies used in this study.**

Antibodies	Brand	Application	Dilution
LGR6	Sigma, HPA008556	WB	1:1000
E-Cadherin	BD Biosciences, 610181	WB	1:1000
beta-Catenin	Cell Signaling Technologies (CST) #8480	WB	1:1000
phospho-beta-Catenin (Ser675)	CST #4176	WB	1:1000
GAPDH	Santa Cruz Biotechnology (SCBT), sc-25778	WB	1:1000
Mouse IgG-HRP	SCBT, sc-2005	WB	1:2500
Rabbit IgG-HRP	CST, #7074	WB	1:2500
LGR6	Sigma, HPA008556	IF	1:50
beta-Catenin	CST, #8480	IF	1:100
Mouse IgG-FITC	SCBT, sc-2010	IF	1:100
Rabbit IgG-FITC	SCBT, sc-2012	IF	1:100
Mouse IgG-TR	SCBT, sc-2781	IF	1:100
LGR6 APC-conjugated	R&D Systems, FAB8458A-025	Flowcytometry Acc. to manufacturer	

**Supplementary Table 2. Common genes of overlap analysis (TCGA and CCLE data) with comparison of LGR6<sup>high</sup> to LGR6<sup>low</sup> expression (related to VENN diagram in Supplementary Figure 3).**

ID	Full name
AKR1B10	aldo-keto reductase family 1 member B10
ALDH1A1	aldehyde dehydrogenase 1 family member A1
ALDH3A1	aldehyde dehydrogenase 3 family member A1
ANO1	anoctamin 1
BCHE	butyrylcholinesterase
BMP4	bone morphogenetic protein 4
BST2	bone marrow stromal cell antigen 2
CEACAM5	CEA cell adhesion molecule 5
CEACAM6	CEA cell adhesion molecule 6
CLIC3	chloride intracellular channel 3
CXCL14	C-X-C motif chemokine ligand 14
DPP4	dipeptidyl peptidase 4
EDAR	ectodysplasin A receptor
FGF19	fibroblast growth factor 19
FGFBP1	fibroblast growth factor binding protein 1
GPX3	glutathione peroxidase 3
KLK10	kallikrein related peptidase 10
KRT14	keratin 14
KRT17	keratin 17
KRT6A	keratin 6A
LY6D	lymphocyte antigen 6 family member D
MSLN	mesothelin
PLA2G10	phospholipase A2 group X
PRR15	proline rich 15
PSCA	prostate stem cell antigen
S100P	S100 calcium binding protein P

SERPINB5	serpin family B member 5
SPESP1	sperm equatorial segment protein 1
SPRR1B	small proline rich protein 1B
SPRR3	small proline rich protein 3

**Supplementary Table 3. Clinical data (TCGA) in correlation with LGR6 mRNA expression in pancreatic ductal adenocarcinoma.**

Characteristics	Total	LGR6		P
		Low	High	
All patients	178 (100.0)	62 (34.8)	116 (65.2)	
<b>Gender</b>				
Male	95 (56.5)	33 (34.7)	62 (65.3)	0.87
Female	73 (43.5)	24 (32.9)	49 (67.1)	
<b>T-category</b>				
T1	8 (5.0)	1 (12.5)	7 (87.5)	0.5696
T2	19 (11.8)	12 (63.2)	7 (36.8)	
T3	131 (81.4)	42 (32.1)	89 (67.9)	
T4	3 (1.8)	1 (33.3)	2 (66.7)	
<b>Nodal Metastasis</b>				
Negative	42 (26.6)	15 (35.7)	27 (64.3)	0.8504
Positive	116 (73.4)	39 (33.6)	77 (66.4)	
<b>Distant Metastasis</b>				
Negative	74 (45.7)	26 (35.1)	48 (64.9)	>0.9999
Positive	88 (54.3)	31 (35.2)	57 (64.8)	
<b>Diabetes</b>				
Negative	98 (73.1)	35 (35.7)	63 (64.3)	>0.9999
Positive	36 (26.9)	13 (36.1)	23 (63.9)	
<b>Alcohol history</b>				
Negative	57 (37.5)	22 (38.6)	35 (61.4)	0.7277
Positive	95 (62.5)	33 (34.7)	62 (65.3)	
<b>History Chronic Pancreatitis</b>				
Negative	117 (90.7)	43 (36.8)	74 (63.2)	>0.9999
Positive	12 (9.3)	4 (33.3)	8 (66.7)	

Values in parentheses indicate column and row percentage for total and LGR6 low or high cases, respectively.